EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Macrolide resistance in Mycobacterium abscessus : current insights and future perspectives

Victoria L Nguyen, Kelly L Eick, Mingyu Gan, Taryn A Miner, Anne E Friedland, Allison F Carey, Kenneth N Olivier, Qingyun Liu iD

JAC-Antimicrobial Resistance · 04.03.2025 · 7 (2)

DOI: 10.1093/jacamr/dlaf047 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift JAC-Antimicrobial Resistance, online erschienen am 02.04.2025. Verfasst von Victoria L Nguyen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mycobacterium abscessus (MAB) is a rapidly growing, non-tuberculous mycobacterium that has emerged as a significant pathogen in both pulmonary and extrapulmonary infections. It is rising in prevalence, especially among individuals with underlying lung conditions such as cystic fibrosis and chronic obstructive pulmonary disease, highlighting its growing clinical importance. The treatment of MAB infections is notoriously challenging due to intrinsic resistance to many antibiotics and low cure rates, typically <50%. Macrolides are a cornerstone in the treatment of MAB infections because regimens that include effective macrolide therapy are associated with higher cure rates. However, MAB possesses intrinsic and acquired drug resistance mechanisms against macrolides, complicating drug susceptibility testing and selection of highly effective treatment regimens. This review aims to provide a summary of the current understanding of macrolide resistance mechanisms in MAB. We explored the epidemiology of resistance in different countries and the molecular mechanisms involved. We have highlighted the variability in sensitivity of existing markers to predict phenotypic macrolide drug resistance across different countries, suggesting the involvement of unknown resistance mechanisms. By synthesizing current knowledge and identifying gaps in the literature, this review seeks to inform clinical practice and guide future research efforts in the fight against MAB drug resistance.

Autor:innen und Institutionen

  • Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Division of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
  • Department of Pathology, University of Utah, Salt Lake City, UT 84112, USA.
  • Marsico Lung Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

ORCID-Profile: Qingyun Liu

Förderung

  • NIAID NIH HHS

Zitieren

APA

Nguyen, V. L., Eick, K. L., Gan, M., Miner, T. A., Friedland, A. E., Carey, A. F., Olivier, K. N., & Liu, Q. (2025). Macrolide resistance in Mycobacterium abscessus : current insights and future perspectives. JAC-Antimicrobial Resistance, 7(2). https://doi.org/10.1093/jacamr/dlaf047

Vancouver

Nguyen VL, Eick KL, Gan M, Miner TA, Friedland AE, Carey AF, et al. Macrolide resistance in Mycobacterium abscessus : current insights and future perspectives. JAC-Antimicrobial Resistance. 2025;7(2). doi:10.1093/jacamr/dlaf047

BibTeX
@article{Nguyen2025,
  author = {Nguyen, Victoria L and Eick, Kelly L and Gan, Mingyu and Miner, Taryn A and Friedland, Anne E and Carey, Allison F and Olivier, Kenneth N and Liu, Qingyun},
  title = {Macrolide resistance in Mycobacterium abscessus : current insights and future perspectives},
  journal = {JAC-Antimicrobial Resistance},
  year = {2025},
  volume = {7},
  number = {2},
  doi = {10.1093/jacamr/dlaf047}
}
Kostenlos starten →